Vericel Corporation
VCEL · Price history
Price at last available close
$41.09
+$0.48 (+1.18%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Vericel Corporation
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children.
How they make money
Vericel is a commercial-stage biopharmaceutical company that develops, manufactures, and sells autologous cell therapies and specialty biologics. The company generates revenue primarily through the sale of its proprietary products to hospitals and medical centers, which use these therapies to treat patients in the sports medicine and severe burn care markets.
Products & services
The company's portfolio includes MACI (autologous cultured chondrocytes on porcine collagen membrane) for knee cartilage repair, Epicel (cultured epidermal autografts) for severe burns, and NexoBrid for eschar removal in thermal burns.
Brands & revenue mix
Autologous cultured chondrocytes on porcine collagen membrane for knee cartilage repair.
Separate brand revenue is not available in this research.Source
Cultured epidermal autografts for severe burns.
Separate brand revenue is not available in this research.Source
Biological orphan product for eschar removal in thermal burns.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party suppliers and contract manufacturers for certain raw materials, components, and manufacturing services.Source
Business relationships & partnerships
- MediWound Ltd. — A commercial collaboration and license agreement under which Vericel holds the exclusive rights to commercialize NexoBrid in North America.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
40
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
71
Strong
Financial Strength
65
Business Quality / Moat
92
Management
79
Growth Quality
56
Risk / Durability
40
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
28
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
42/100
Building Historical Record
Model Score 42/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for VCEL
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can VCEL maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is VCEL's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Does VCEL's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What future growth or profitability would be needed to justify VCEL's current valuation?
Essential Investment Snapshot
Wall Street Score
40
Opportunity Score
28
Market Cap
$2.10B
P/E Ratio
89.6
EPS
$0.48
52-Week High
$49.32
52-Week Low
$28.95
Beta
1.02
Intrinsic Value
$18.48
Analyst Target
$60.00
Shares Outstanding
52.1M
Total Revenue
$306.3M
Total Debt
$92.5M
Dividend
No current dividend
Liquidation Value / Share
$7.11
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on VCEL.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Fully-integrated commercial-stage biopharmaceutical platform.
- +Differentiated portfolio of autologous cell therapies.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on third-party suppliers and contract manufacturers.
- −Regulatory risks associated with clinical trials and product approvals.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
40
Oct 1, 2026
Change
-0.1
points
Current Score
40
Oct 26, 2026
Category Changes
VCEL decreased 0.1 points because some fundamentals weakened.
Projected Score
Projected Score
39
Projected Change
-1.4 points
Preliminary comparable-period financial changes suggest decline of approximately 1.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$41.09
Model Intrinsic Value
$18.48
Difference
+$22.61
+122.3% vs IV
Margin of Safety
-122.3%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $306.3M | $276.3M | $237.2M | $197.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $77.9M | $70.7M | $65.1M | $61.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $228.4M | $205.6M | $172.1M | $135.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $29.2M | $27.6M | $24.8M | $21.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $181.0M | $167.0M | $142.8M | $121.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $210.1M | $194.6M | $167.6M | $142.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $38.8M | $30.3M | $16.6M | $2.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $18.2M | $11.0M | $4.5M | -$6.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $640K | $1.6M | $614K | $600K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $25.1M | $17.4M | $10.5M | -$2.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $859K | $859K | $148K | $814K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $24.2M | $16.5M | $10.4M | -$3.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $0.48 | $0.33 | $0.21 | $-0.07 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 50.92M | 50.59M | 48.85M | 47.59M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 50.92M | 52.07M | 51.68M | 47.59M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$77.5M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.04
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-7.2%
Cash Change
+55.7%
Margin Change
+3.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels, net income margin. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 22.5%. EPS declined 463.6%. Cash increased 55.7%. Total debt declined 7.2%. Net income margin improved by 3.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel: MACI And Regenerative Knee Cartilage
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
Rumor Mill · VCEL
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial